Trial Profile
An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Simlukafusp alfa (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 10 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results assessing safety, pharmacokinetics and therapeutic activity of simlukafusp alpha in combination with atezolizumab and bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Planned End Date changed from 19 Mar 2021 to 14 Jun 2021.